ProShare Advisors
VRDN icon

ProShare Advisors’s Viridian Therapeutics VRDN Stock Holding History

ProShare Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
11,825
+31
+0.3% +$499 ﹤0.01% 1592
2026
Q1 		$231K Sell
11,794
-2,809
-19% -$83.4K ﹤0.01% 1488
2025
Q4 		$454K Buy
14,603
+2,597
+22% +$71.2K ﹤0.01% 1182
2025
Q3 		$259K Sell
12,006
-2,239
-16% -$40.4K ﹤0.01% 1534
2025
Q2 		$199K Sell
14,245
-1,907
-12% -$25.9K ﹤0.01% 1724
2025
Q1 		$218K Sell
16,152
-4,432
-22% -$75.5K ﹤0.01% 1637
2024
Q4 		$395K Buy
20,584
+8,761
+74% +$190K ﹤0.01% 1427
2024
Q3 		$269K Buy
+11,823
New +$193K ﹤0.01% 1535

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ProShare Advisors's VRDN Position: Q2 2026 in Review

ProShare Advisors increased its Viridian Therapeutics (VRDN) stake by 0.26% in Q2 2026, buying an estimated $499 and bringing the position to 11,825 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

ProShare Advisors first reported a position in VRDN in Q3 2024 and has held it in 8 quarters since. The position peaked at $454K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • ProShare Advisors held 11,825 shares of Viridian Therapeutics worth $217K as of Q2 2026.
  • ProShare Advisors bought 31 Viridian Therapeutics shares in Q2 2026, an estimated $499.
  • Viridian Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1592 holding.
  • ProShare Advisors first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • ProShare Advisors's Viridian Therapeutics position peaked at $454K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.